SI1154993T1 - Thioamide derivatives - Google Patents

Thioamide derivatives

Info

Publication number
SI1154993T1
SI1154993T1 SI200030513T SI200030513T SI1154993T1 SI 1154993 T1 SI1154993 T1 SI 1154993T1 SI 200030513 T SI200030513 T SI 200030513T SI 200030513 T SI200030513 T SI 200030513T SI 1154993 T1 SI1154993 T1 SI 1154993T1
Authority
SI
Slovenia
Prior art keywords
thioamide derivatives
vcam
vla
asthma
discovered
Prior art date
Application number
SI200030513T
Other languages
English (en)
Slovenian (sl)
Inventor
Kenneth Gregory Hull
Achytharao Sidduri
Jefferson Wright Tilley
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI1154993T1 publication Critical patent/SI1154993T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/46—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
SI200030513T 1999-02-18 2000-02-10 Thioamide derivatives SI1154993T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12047599P 1999-02-18 1999-02-18
EP00903680A EP1154993B1 (en) 1999-02-18 2000-02-10 Thioamide derivatives
PCT/EP2000/001058 WO2000048994A1 (en) 1999-02-18 2000-02-10 Thioamide derivatives

Publications (1)

Publication Number Publication Date
SI1154993T1 true SI1154993T1 (en) 2004-12-31

Family

ID=22390545

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030513T SI1154993T1 (en) 1999-02-18 2000-02-10 Thioamide derivatives

Country Status (29)

Country Link
US (6) US6288267B1 (xx)
EP (1) EP1154993B1 (xx)
JP (1) JP2002537286A (xx)
KR (1) KR100649819B1 (xx)
CN (1) CN1213025C (xx)
AT (1) ATE278664T1 (xx)
AU (1) AU773388B2 (xx)
BR (1) BR0008280A (xx)
CA (1) CA2362831C (xx)
CZ (1) CZ20012980A3 (xx)
DE (1) DE60014588T2 (xx)
DK (1) DK1154993T3 (xx)
ES (1) ES2228458T3 (xx)
HK (1) HK1044330A1 (xx)
HR (1) HRP20010595B1 (xx)
HU (1) HUP0200155A3 (xx)
ID (1) ID30129A (xx)
IL (2) IL144636A0 (xx)
MA (1) MA26769A1 (xx)
NO (1) NO20014018D0 (xx)
NZ (1) NZ513254A (xx)
PL (1) PL349461A1 (xx)
PT (1) PT1154993E (xx)
RU (1) RU2245874C2 (xx)
SI (1) SI1154993T1 (xx)
TR (1) TR200102399T2 (xx)
WO (1) WO2000048994A1 (xx)
YU (1) YU58701A (xx)
ZA (1) ZA200106180B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6521626B1 (en) * 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
EP2267043A1 (en) * 2000-01-26 2010-12-29 Mitsui Chemicals, Inc. Tapered olefin copolymer of very low polydispersity and process for preparing the same
AU2001242743A1 (en) * 2000-03-23 2001-10-03 Ajinomoto Co. Inc. Novel phenylalanine derivative
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
NZ525143A (en) * 2000-09-14 2005-12-23 Gruenenthal Chemie Beta-thio-amino acids
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050069227A1 (en) * 2003-09-29 2005-03-31 Mark Steele Flexible package having integrated slit member
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20050209232A1 (en) * 2004-02-10 2005-09-22 Kent Barbay Pyridazinone ureas as antagonists of alpha4 integrins
JP2007522225A (ja) * 2004-02-10 2007-08-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ａ４インテグリン拮抗薬としてのピリダジノン
WO2005087760A1 (en) * 2004-03-10 2005-09-22 Merck & Co., Inc. Vla-4 antagonists
ATE430761T1 (de) * 2004-08-16 2009-05-15 Merck & Co Inc Vla-4-antagonisten
US7641325B2 (en) * 2004-10-04 2010-01-05 Kodak Graphic Communications Group Canada Non-conductive fluid droplet characterizing apparatus and method
WO2006081986A1 (en) * 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Bambuterol and integrin inhibitor combination
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
CZ297581B6 (cs) * 2005-05-26 2007-01-10 Universita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Antimykotické a antimykobakteriální thiosalicylanilidy a způsob jejich přípravy
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
NZ585556A (en) * 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8343706B2 (en) * 2010-01-25 2013-01-01 International Business Machines Corporation Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same
CA2848587A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Methods of risk assessment of pml and related apparatus
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
KR102652797B1 (ko) 2018-10-30 2024-04-02 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린의 억제를 위한 화합물
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
EP3873605A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN113683499B (zh) * 2021-09-10 2024-01-30 上海皓鸿生物医药科技有限公司 一种制备杜韦利西布中间体的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE584914A (xx) 1958-11-24
US3527793A (en) 1967-08-18 1970-09-08 Bristol Myers Co Phenylglycine derivatives
IT1190378B (it) 1985-06-21 1988-02-16 Isf Spa Derivati pirrolidonici
US5039805A (en) 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
ATE210663T1 (de) 1994-06-20 2001-12-15 Takeda Chemical Industries Ltd Kondensierte imidazolderivate, ihre herstellung und verwendung
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5804595A (en) 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
WO1997036862A1 (en) 1996-03-29 1997-10-09 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
PT891325E (pt) * 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
DE19654483A1 (de) 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
JP2001517246A (ja) * 1997-06-23 2001-10-02 田辺製薬株式会社 α▲下４▼β▲下１▼媒介細胞接着の阻止剤
AU8823498A (en) * 1997-07-31 1999-02-22 American Home Products Corporation Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
CA2290750A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
CA2291475A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
US6229011B1 (en) * 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
PL193283B1 (pl) * 1997-08-22 2007-01-31 Hoffmann La Roche Nowe pochodne N-aroilofenyloalaniny, ich zastosowanie i środek leczniczy
CN1276785A (zh) 1997-08-22 2000-12-13 霍夫曼-拉罗奇有限公司 N－烷酰基苯丙氨酸衍生物
JP4555469B2 (ja) * 1997-12-23 2010-09-29 アベンテイス・フアルマ・リミテツド 置換されたβ−アラニン
ES2226413T3 (es) 1998-02-26 2005-03-16 Celltech Therapeutics Limited Derivados de fenilalanina como inhibidores de alfa-4 integrinas.
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
IL144636A (en) 2007-06-17
HRP20010595B1 (en) 2006-02-28
KR20010102243A (ko) 2001-11-15
YU58701A (sh) 2004-05-12
CN1213025C (zh) 2005-08-03
US6458844B2 (en) 2002-10-01
ES2228458T3 (es) 2005-04-16
DK1154993T3 (da) 2005-02-14
US6423728B1 (en) 2002-07-23
NO20014018L (no) 2001-08-17
US6426348B1 (en) 2002-07-30
HRP20010595A2 (en) 2002-08-31
US20020010338A1 (en) 2002-01-24
ATE278664T1 (de) 2004-10-15
AU773388B2 (en) 2004-05-27
NO20014018D0 (no) 2001-08-17
EP1154993B1 (en) 2004-10-06
HUP0200155A3 (en) 2005-04-28
MA26769A1 (fr) 2004-12-20
TR200102399T2 (tr) 2002-01-21
DE60014588D1 (en) 2004-11-11
US20010041799A1 (en) 2001-11-15
PT1154993E (pt) 2005-01-31
US6479666B2 (en) 2002-11-12
CA2362831A1 (en) 2000-08-24
RU2245874C2 (ru) 2005-02-10
ID30129A (id) 2001-11-08
IL144636A0 (en) 2002-05-23
JP2002537286A (ja) 2002-11-05
US6288267B1 (en) 2001-09-11
ZA200106180B (en) 2002-10-28
US20020028933A1 (en) 2002-03-07
AU2547500A (en) 2000-09-04
CA2362831C (en) 2008-10-07
CZ20012980A3 (cs) 2002-04-17
NZ513254A (en) 2003-10-31
PL349461A1 (en) 2002-07-29
KR100649819B1 (ko) 2007-02-28
US20020040148A1 (en) 2002-04-04
EP1154993A1 (en) 2001-11-21
US20020052508A1 (en) 2002-05-02
BR0008280A (pt) 2001-11-06
CN1342140A (zh) 2002-03-27
HK1044330A1 (en) 2002-10-18
HUP0200155A2 (en) 2002-06-29
WO2000048994A1 (en) 2000-08-24
DE60014588T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
IL144636A0 (en) Thioamide derivatives
BG108806A (en) IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF
MXPA01008058A (es) Composiciones deinhibidor de cicloxigenasa-2 teniendo un rapido inicio de efecto terapeutico.
UA84175C2 (ru) Гетероциклические ингибиторы мэк и их применение
MY126972A (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
EP1017382A4 (en) BIARYLALKANOIC ACID FOR USE AS A CELL ADHESION INHIBITOR
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
CA2505964A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
JO2281B1 (en) Phenylalanine-L-acyl-N-pyridine-4
EP1539136A4 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
AU2003224923A1 (en) Heterocyclic amide derivatives as cytokine inhibitors
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
CA2362833A1 (en) Phenylalaninol derivatives
PL1716147T3 (pl) Pochodne diazaspiropiperydyny jako inhibitory transportera 1 glicyny i transportera 2 glicyny
EP1619184A3 (en) Urea compounds as kinase inhibitors
WO1998057910A3 (en) Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents
WO2004042342A3 (en) Nuclear pore protein nup88 as a novel target